Sensi.AI, a pioneering leader in care intelligence, has announced a significant milestone with the successful completion of a $31 million Series B funding round. This latest infusion, co-led by Zeev Ventures and Insight Partners, alongside existing investors Entrée Capital, Flint Capital, Jibe Ventures, and Secret Chord Ventures, brings Sensi.AI’s total funding to over $53 million….
UroMems, a pioneering global company specializing in mechatronics technology for treating stress urinary incontinence (SUI), has secured $47 million in its Series C financing round, marking a record fundraising achievement for the company. This capital infusion will propel pivotal clinical trials of their groundbreaking UroActive™ System, the world’s first smart automated artificial urinary sphincter (AUS)…
Since its inception, Ethris GmbH has been a trailblazer in mRNA technology, revolutionizing the biotech landscape with its innovative approach to respiratory and cardiovascular diseases. Founded on a vision of harnessing messenger RNA (mRNA) for therapeutic breakthroughs, Ethris has consistently pushed boundaries, drawing attention from investors and global biotech leaders alike. Breakthroughs and Strategic Growth…
PolTREG S.A., a pioneering biotechnology firm specializing in cellular therapies for autoimmune disorders, has announced groundbreaking findings from its long-term clinical study on PTG-007, a polyclonal Treg cell therapy for early-onset type-1 diabetes (T1D). Over a span of 7 to 12 years, pediatric patients treated with PTG-007 demonstrated sustained insulin secretion, contrasting starkly with a…
Marea Therapeutics has marked a significant milestone with the successful closure of a $190 million combined Series A and B financing, positioning the clinical-stage biotechnology firm to accelerate its pioneering efforts in cardiometabolic disease treatments. Led by Third Rock Ventures and supported by a consortium of leading investors including Sofinnova Investments, Forbion, and Perceptive Xontogeny…
